A Phase 3 interventional study of Poliorix™ and Oral Poliovirus vaccine in Poliomyelitis and Poliomyelitis Vaccines, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 60 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-21.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis — 3 open to participants now, 3 under way, none of them phase 3. Poliovirus Vaccine, Inactivated · Poliomyelitis.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, this one is the 5th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 2nd registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →3 of the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis are open now, in 1 country. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–50 yrs · Healthy volunteers
Institute of Medical Biology, Chinese Academy of Medical Sciences · Sites in China
Ages 2 mo–2 mo · Healthy volunteers
International Centre for Diarrhoeal Disease Research, Bangladesh
Ages 42 days–48 days · Healthy volunteers
By country, each count listing its studies:
Poliovirus Vaccine, Inactivated: first FDA approval 2002 (Pediarix). What it is approved for, and how studies give it, is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 60 Days to 90 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 4 · Phase 4 11
First in 2009; this study’s year is marked. 2 started in 2009.
This study's enrollment of 1,101 is above the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 672 across the 18 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Poliomyelitis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 30 (70%) have results posted.
Among the 44 studies in Poliomyelitis by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2009, is one of 20 in phase 3, and was the 22nd registered.
GlaxoSmithKline’s Poliomyelitis studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 44 in Poliomyelitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved and if no other exclusion criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
Biological: Poliorix™
Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
Biological: Oral Poliovirus vaccine
3 doses, intramuscular administration
3 doses, oral administration
Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3
A seroprotected subject was defined as a vaccinated subject with anti-polio types 1, 2 and 3 titers greater than or equal to (≥) 8 effective dose 50 (ED50).
Time frame: At Month 3, one month after the third vaccine dose
Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3
A seroprotected subject was defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 titers ≥ 8 ED50.
Time frame: At Day 0, prior to the first vaccine dose
Anti-poliovirus Types 1, 2 and 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs).
Time frame: Prior to the first vaccine dose (Day 0) and one month after the third vaccine dose (Month 3)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure concerns subjects from the Poliorix Group only.
Time frame: During the 4-day (Days 0-3) post-vaccination period following each vaccine dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, gastrointestinal symptoms, irritability/fussiness, loss of appetite and fever \[defined as axillary temperature higher than (\>) 37.0°C degrees Celsius\]. Gastrointestinal symptoms included nausea, vomiting, diarrhoea and/or abdominal pain. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 gastrointestinal symptoms = gastrointestinal symptoms that prevented normal activity. Grade 3 fever= temperature \> 39°C. Related = symptom assessed by the investigator as causally related to the vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period following each vaccine dose and across doses
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within the 31-day (Days 0-30) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity.
Time frame: During the entire study period (from Day 0 to Month 3)
Of the 1101 enrolled subjects, one subject was not randomised and administered any vaccine as the parents of the subject refused to vaccinate their child after blood collection at Visit 1 and withdrew their consent.
| Milestone | Poliorix Group | Control Group |
|---|---|---|
| Started | 550 | 550 |
| Completed | 538 | 526 |
| Not completed | 12 | 24 |
| Withdrew: Serious adverse event | 2 | 1 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Migrated/moved from study area | 6 | 18 |
| Withdrew: Lost to follow-up | 1 | 1 |
A seroprotected subject was defined as a vaccinated subject with anti-polio types 1, 2 and 3 titers greater than or equal to (≥) 8 effective dose 50 (ED50).
| Participants | Poliorix Group | Control Group |
|---|---|---|
| Anti-poliovirus 1 | 306 | 296 |
| Anti-poliovirus 2 | 306 | 296 |
| Anti-poliovirus 3 | 306 | 291 |
A seroprotected subject was defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 titers ≥ 8 ED50.
| Participants | Poliorix Group | Control Group |
|---|---|---|
| Anti-poliovirus 1 | 131 | 113 |
| Anti-poliovirus 2 | 93 | 99 |
| Anti-poliovirus 3 | 48 | 52 |
Antibody titers were presented as geometric mean titers (GMTs).
| Titers | Poliorix Group | Control Group |
|---|---|---|
| Anti-poliovirus 1, D0 | 8.7 (7.6 to 9.8) | 7.8 (6.9 to 8.9) |
| Anti-poliovirus 1, M3 | 485.1 (436.7 to 538.9) | 2817 (2479.5 to 3200.4) |
| Anti-poliovirus 2, D0 | 6.5 (5.9 to 7.1) | 7.2 (6.5 to 8.1) |
| Anti-poliovirus 2, M3 | 234.3 (209 to 262.6) | 468.5 (416.6 to 526.9) |
| Anti-poliovirus 3, D0 | 5.2 (4.8 to 5.7) | 5.2 (4.8 to 5.7) |
| Anti-poliovirus 3, M3 | 824.3 (725.3 to 936.9) | 423.4 (363.3 to 493.3) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure concerns subjects from the Poliorix Group only.
| Participants | Poliorix Group |
|---|---|
| Any Pain, Dose 1 | 80 |
| Grade 3 Pain, Dose 1 | 1 |
| Any Redness, Dose 1 | 20 |
| Grade 3 Redness, Dose 1 | 0 |
| Any Swelling, Dose 1 | 9 |
| Grade 3 Swelling, Dose 1 | 0 |
| Any Pain, Dose 2 | 58 |
| Grade 3 Pain, Dose 2 | 2 |
| Any Redness, Dose 2 | 23 |
| Grade 3 Redness, Dose 2 | 1 |
| Any Swelling, Dose 2 | 8 |
| Grade 3 Swelling, Dose 2 | 1 |
| Any Pain, Dose 3 | 41 |
| Grade 3 Pain, Dose 3 | 0 |
| Any Redness, Dose 3 | 15 |
| Grade 3 Redness, Dose 3 | 0 |
| Any Swelling, Dose 3 | 6 |
| Grade 3 Swelling, Dose 3 | 0 |
| Any Pain, Across doses | 113 |
| Grade 3 Pain, Across doses | 3 |
| Any Redness, Across doses | 46 |
| Grade 3 Redness, Across doses | 1 |
| Any Swelling, Across doses | 18 |
| Grade 3 Swelling, Across doses | 1 |
Assessed solicited general symptoms were drowsiness, gastrointestinal symptoms, irritability/fussiness, loss of appetite and fever \[defined as axillary temperature higher than (\>) 37.0°C degrees Celsius\]. Gastrointestinal symptoms included nausea, vomiting, diarrhoea and/or abdominal pain. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 gastrointestinal symptoms = gastrointestinal symptoms that prevented normal activity. Grade 3 fever= temperature \> 39°C. Related = symptom assessed by the investigator as causally related to the vaccination.
| Participants | Poliorix Group | Control Group |
|---|---|---|
| Any Drowsiness, Dose 1 | 99 | 75 |
| Grade 3 Drowsiness, Dose 1 | 0 | 1 |
| Related Drowsiness, Dose 1 | 71 | 51 |
| Any Gastrointestinal Symptoms, Dose 1 | 102 | 89 |
| Grade 3 Gastrointestinal, Dose 1 | 0 | 2 |
| Related Gastrointestinal, Dose 1 | 44 | 43 |
| Any Irritability/Fussiness, Dose 1 | 160 | 151 |
| Grade 3 Irritability/Fussiness, Dose 1 | 1 | 5 |
| Related Irritability/Fussiness, Dose 1 | 130 | 105 |
| Any Loss of appetite, Dose 1 | 82 | 83 |
| Grade 3 Loss of appetite, Dose 1 | 0 | 1 |
| Related Loss of appetite, Dose 1 | 54 | 47 |
| Any temperature, Dose 1 | 39 | 20 |
| Grade 3 temperature, Dose 1 | 0 | 0 |
| Related temperature, Dose 1 | 28 | 10 |
| Any Drowsiness, Dose 2 | 68 | 50 |
| Grade 3 Drowsiness, Dose 2 | 2 | 0 |
| Related Drowsiness, Dose 2 | 51 | 25 |
| Any Gastrointestinal, Dose 2 | 66 | 67 |
| Grade 3 Gastrointestinal, Dose 2 | 2 | 1 |
| Related Gastrointestinal, Dose 2 | 32 | 35 |
| Any Irritability/Fussiness, Dose 2 | 121 | 86 |
| Grade 3 Irritability/Fussiness, Dose 2 | 7 | 2 |
| Related Irritability/Fussiness, Dose 2 | 105 | 50 |
| Any Loss of appetite, Dose 2 | 70 | 78 |
| Grade 3 Loss of appetite, Dose 2 | 3 | 0 |
| Related Loss of appetite, Dose 2 | 48 | 47 |
| Any temperature, Dose 2 | 39 | 26 |
| Grade 3 temperature, Dose 2 | 2 | 1 |
| Related temperature, Dose 2 | 29 | 11 |
| Any Drowsiness, Dose 3 | 47 | 45 |
| Grade 3 Drowsiness, Dose 3 | 2 | 1 |
| Related Drowsiness, Dose 3 | 36 | 25 |
| Any Gastrointestinal, Dose 3 | 46 | 67 |
| Grade 3 Gastrointestinal, Dose 3 | 3 | 0 |
| Related Gastrointestinal, Dose 3 | 16 | 25 |
| Any Irritability/Fussiness, Dose 3 | 87 | 72 |
| Grade 3 Irritability/Fussiness, Dose 3 | 2 | 2 |
| Related Irritability/Fussiness, Dose 3 | 77 | 44 |
| Any Loss of appetite, Dose 3 | 52 | 64 |
| Grade 3 Loss of appetite, Dose 3 | 0 | 0 |
| Related Loss of appetite, Dose 3 | 34 | 36 |
| Any temperature, Dose 3 | 33 | 32 |
| Grade 3 temperature, Dose 3 | 0 | 2 |
| Related temperature, Dose 3 | 18 | 17 |
| Any Drowsiness, Across doses | 140 | 125 |
| Grade 3 Drowsiness, Across doses | 4 | 2 |
| Related Drowsiness, Across doses | 115 | 80 |
| Any Gastrointestinal, Across doses | 154 | 156 |
| Grade 3 Gastrointestinal, Across doses | 5 | 3 |
| Related Gastrointestinal, Across doses | 76 | 87 |
| Any Irritability, Across doses | 244 | 216 |
| Grade 3 Irritability, Across doses | 10 | 9 |
| Related Irritability, Across doses | 214 | 159 |
| Any Loss of appetite, Across doses | 147 | 168 |
| Grade 3 Loss of appetite, Across doses | 3 | 1 |
| Related Loss of appetite, Across doses | 109 | 109 |
| Any Fever, Across doses | 99 | 71 |
| Grade 3 Fever, Across doses | 2 | 3 |
| Related Fever, Across doses | 68 | 36 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Poliorix Group | Control Group |
|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | 155 | 162 |
Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity.
| Participants | Poliorix Group | Control Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 3 | 6 |
Collected over Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period. Unsolicited AEs: within the 31-day (Days 0-30) post-vaccination period. SAEs: during the entire study period (from Day 0 up to Month 3).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Poliorix Group | 0/550 (0%) | 3/550 (0.5%) | 391/550 (71.1%) |
| Control Group | 0/550 (0%) | 6/550 (1.1%) | 366/550 (66.5%) |
| Event | Poliorix Group | Control Group |
|---|---|---|
| BronchopneumoniaInfections and infestations | 0/550 | 2/550 |
| Cardiac failureCardiac disorders | 0/550 | 1/550 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/550 | 1/550 |
| EpilepsyNervous system disorders | 0/550 | 1/550 |
| HydrocephalusNervous system disorders | 1/550 | 0/550 |
| Abdominal distensionGastrointestinal disorders | 0/550 | 1/550 |
| DiarrhoeaGastrointestinal disorders | 1/550 | 0/550 |
| EnteritisGastrointestinal disorders | 0/550 | 1/550 |
| BronchitisInfections and infestations | 0/550 | 1/550 |
| Herpes zosterInfections and infestations | 1/550 | 0/550 |
| Event | Poliorix Group | Control Group |
|---|---|---|
| Irritability/FussinessGeneral disorders | 244/550 | 216/550 |
| Loss of appetiteGeneral disorders | 147/550 | 168/550 |
| Gastrointestinal symptomsGeneral disorders | 154/550 | 156/550 |
| DrowsinessGeneral disorders | 140/550 | 125/550 |
| PainGeneral disorders | 113/550 | 0/550 |
| Upper respiratory tract infectionInfections and infestations | 99/550 | 97/550 |
| Fever (Axillary)General disorders | 99/550 | 71/550 |
| RednessGeneral disorders | 46/550 | 0/550 |
| NasopharyngitisInfections and infestations | 32/550 | 38/550 |
| Age, Continuous(Weeks) | Poliorix Group | Control Group | Total |
|---|---|---|---|
| Mean | 10 ± 1.16 | 10.1 ± 1.18 | 10.05 ± 1.17 |
| Sex: Female, Male(Participants) | Poliorix Group | Control Group | Total |
|---|---|---|---|
| Female | 268 | 259 | 527 |
| Male | 282 | 291 | 573 |
| Race/Ethnicity, Customized(Participants) | Poliorix Group | Control Group | Total |
|---|---|---|---|
| Asian-Chinese heritage | 550 | 550 | 1100 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Nov 2009 to primary completion in Jul 2010, 7 months.
Results were first posted in Apr 2017, 6 years 9 months after primary completion. A results delay was requested in Dec 2010.
Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 7 months is below that.
Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poliovirus Vaccine, Inactivated